Two studies with multivariate analysis found tumour site to be a prognostic factor, both with some methodological limitations.
Results of the meta-analysis suggest that p53 overexpression might be a prognostic factor for patients with UUTUC.
Recently, the lymphocyte-to-monocyte ratio (LMR) has been reported to be a prognostic factor in multiple malignancies.
HER2 (c-erbB-2) has been suggested to be a prognostic factor in a variety of human cancers including breast, gastric and ovarian cancers.
Admission for a respiratory reason may be a prognostic factor of survival.
Furthermore, ALK expression could be a prognostic factor of aggressiveness for IMT.
The numbers of tumor-infiltrating lymphocytes have been reported to be a prognostic factor [17].
Witnessed arrest has been shown to be a prognostic factor for favorable outcomes in CCPR [26, 34].
This score was initially described in 2003 in patients with inoperable lung cancer and proved to be a prognostic factor for survival [2].
CONCLUSIONS: Our data show that FOLR1 overexpression is not only a biomarker associated with endometrial cancer, but it also appears to be a prognostic factor associated with adverse outcome.
The presence of elevated levels of mutant p53 may itself be a prognostic factor in human breast cancer and activation of this oncogene may be important in the ability of a tumor to metastasize.
